The window Scottsdale has been waiting on is almost open.
The Phoenix-Scottsdale corridor has been one of the most active anti-aging and longevity medicine markets in the country for nearly two decades. Mayo Clinic Arizona's research presence, the dense concentration of concierge primary-care practices along Camelback and Shea, and a year-round retiree and snowbird population that prioritizes vitality have produced a market that is unusually well-informed about peptide therapy and unusually patient about doing it correctly.
That market has been operating quietly, within FDA Category 2 restrictions, for some time. What changes now is the broader regulatory environment. On April 16, 2026, the Federal Register published the FDA's notice convening the Pharmacy Compounding Advisory Committee — the body whose recommendations will determine whether BPC-157, KPV, TB-500, and MOTs-C move from Category 2 (under review, restricted) into Category 1 (clearly eligible for compounding). The committee meets July 23-24, 2026. The PCAC's recommendations are advisory rather than binding, but the FDA has historically aligned with its findings on most bulk substance reclassification decisions.
For patients in Scottsdale, the practical effect is that the longevity-focused physicians and 503A compounding pharmacies who have been quietly preparing are now able to discuss treatment more openly with new patients. They are not selling; they are practicing medicine, and they have been doing so within the existing federal framework.
This directory exists to connect you with those practitioners. We are not affiliated with any clinic. We do not sell peptides. We confirm state licensure, verify the compounding pharmacy relationship, and check the prescriber's board status before any name appears on this site. The national directory is built on the same standard, and what follows is the clinical context every patient considering anti-aging peptide therapy in Scottsdale should understand before scheduling a consult.